Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles

Oncotarget

Volumn 5, Issue 15, 2014, Pages 6453-6465

  Xiong, Xunhao ^a   Arvizo R , Rochelle ^b   Saha, Sounik ^a   Robertson J , David ^c   McMeekin, Scott ^a,d   Bhattacharya, Resham ^a,d   Mukherjee, Priyabrata ^d  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Cancer stem cell; Chemoresistance; EMT; Gold nanoparticle; NF kB

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CISPLATIN; GOLD NANOPARTICLE; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN KINASE B; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; GOLD; METAL NANOPARTICLE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CONTROLLED STUDY; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; SIDE POPULATION CELL; ANIMAL; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CISPLATIN; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG SYNERGISM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GOLD; HUMANS; METAL NANOPARTICLES; MICE; MICE, NUDE; NANOPARTICLES; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906275722     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2203     Document Type: Article

References (50)

1. Agarwal R, Kaye SB. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3(7):502-516.
2. Herzog TJ, Pothuri B. Ovarian cancer: A focus on management of recurrent disease. Nat Clin Pract Oncol 2006; 3(11):604-611.
3. Lili LN, Matyunina LV, Walker LD, Wells SL, Benigno BB, McDonald JF. Molecular profiling supports the role of epithelial-to-mesenchymal transition (emt) in ovarian cancer metastasis. J Ovarian Res 2013; 6(1):49.
4. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, Salzet M. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett 2010; 291(1):59-66.
5. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer research 2009; 69(6):2400-2407.
6. Rosano L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A. Acquisition of chemoresistance and emt phenotype is linked with activation of the endothelin a receptor pathway in ovarian carcinoma cells. Clin Cancer Res 2011; 17(8):2350-2360.
7. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science 2009; 324(5935):1670-1673.
8. McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng KH, Daggett J, Jr., Cullen K, Kantoff E, Hasselbatt K, Berkowitz J, Muto MG, et al. Targeting notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci USA 2012; 109(43):E2939-2948.
9. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: Models and concepts. Annu Rev Med 2007; 58:267-284.
10. Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 2010; 10(3):268-278.
11. Yew KH, Crow J, Hirst J, Pressetto Z, Godwin AK. Epimorphin-induced met sensitizes ovarian cancer cells to platinum. PloS one 2013; 8(9):e72637.
12. Arvizo RR, Miranda OR, Thompson MA, Pabelick CM, Bhattacharya R, Robertson JD, Rotello VM, Prakash YS, Mukherjee P. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett 2010; 10(7):2543-2548.
13. Li C, Li L, Keates AC. Targeting cancer gene therapy with magnetic nanoparticles. Oncotarget 2012; 3(4):365-370.
14. Auffinger B, Morshed R, Tobias A, Cheng Y, Ahmed AU, Lesniak MS. Drug-loaded nanoparticle systems and adult stem cells: A potential marriage for the treatment of malignant glioma? Oncotarget 2013; 4(3):378-396.
15. Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: Application of nanotechnology in cancer therapy. Drug Discov Today 2010; 15(19-20):842-850.
16. Mukherjee P, Bhattacharya R, Wang P, Wang L, Basu S, Nagy JA, Atala A, Mukhopadhyay D, Soker S. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 2005; 11(9):3530-3534.
17. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, Jain RK. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012; 7(6):383-388.
18. Qiao Y, Huang X, Nimmagadda S, Bai R, Staedtke V, Foss CA, Cheong I, Holdhoff M, Kato Y, Pomper MG, Riggins GJ, Kinzler KW, Diaz LA, Jr., Vogelstein B, Zhou S. A robust approach to enhance tumor-selective accumulation of nanoparticles. Oncotarget 2011; 2(1-2):59-68.
19. Sequeira G, Vanzulli SI, Rojas P, Lamb C, Colombo L, May M, Molinolo A, Lanari C. The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the pr isoform ratio in preclinical models of breast cancer. Oncotarget 2014; 5(10):3246-3260.
20. Arvizo RR, Saha S, Wang E, Robertson JD, Bhattacharya R, Mukherjee P. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci USA 2013; 110(17):6700-6705.
21. Arvizo RR, Rana S, Miranda OR, Bhattacharya R, Rotello VM, Mukherjee P. Mechanism of anti-angiogenic property of gold nanoparticles: Role of nanoparticle size and surface charge. Nanomedicine 2011; 7(5):580-587.
22. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell 2009; 139(5):871-890.
23. Wang H, Zhang G, Zhang H, Zhang F, Zhou B, Ning F, Wang HS, Cai SH, Du J. Acquisition of epithelialmesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through akt/beta-catenin/snail signaling pathway. Eur J Pharmacol 2014; 723:156-166.
24. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F, Papaccio G. Cancer stem cells in solid tumors: An overview and new approaches for their isolation and characterization. Faseb J 2013; 27(1):13-24.
25. Burgos-Ojeda D, Rueda BR, Buckanovich RJ. Ovarian cancer stem cell markers: Prognostic and therapeutic implications. Cancer Lett 2012; 322(1):1-7.
26. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006; 103(30):11154-11159.
27. Perkins ND. Integrating cell-signalling pathways with nfkappab and ikk function. Nat Rev Mol Cell Biol 2007; 8(1):49-62.
28. Yamamoto M, Taguchi Y, Ito-Kureha T, Semba K, Yamaguchi N, Inoue J. Nf-kappab non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nat Commun 2013; 4:2299.
29. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC. Pten/pi3k/akt pathway regulates the side population phenotype and abcg2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009; 4(3):226-235.
30. Arafa el SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA, Wani AA. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/akt signaling pathway. Cancer Res 2009; 69(23):8910-8917.
31. Sun H, Zheng X, Wang Q, Yan J, Li D, Zhou Y, Lin Y, Zhang L, Wang X. Concurrent blockade of nf-kappab and akt pathways potentiates cisplatin's antitumor activity in vivo. Anti-cancer Drugs 2012; 23(10):1039-1046.
32. Hernandez-Flores G, Ortiz-Lazareno PC, Lerma-Diaz JM, Dominguez-Rodriguez JR, Jave-Suarez LF, Aguilar-Lemarroy Adel C, de Celis-Carrillo R, del Toro-Arreola S, Castellanos-Esparza YC, Bravo-Cuellar A. Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing nf-kappa b and decreased cell senescence. BMC Cancer 2011; 11:483.
33. Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D. Biological and chemical inhibitors of nfkappab sensitize siha cells to cisplatin-induced apoptosis. Mol Carcinog 2005; 44(1):51-59.
34. Parajuli B, Lee HG, Kwon SH, Cha SD, Shin SJ, Lee GH, Bae I, Cho CH. Salinomycin inhibits akt/nf-kappab and induces apoptosis in cisplatin resistant ovarian cancer cells. Cancer Epidemiol 2013; 37(4):512-517.
35. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006; 107(6):1399-1410.
36. Ferrell B, Smith SL, Cullinane CA, Melancon C. Psychological well being and quality of life in ovarian cancer survivors. Cancer 2003; 98(5):1061-1071.
37. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J.A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141(1):69-80.
38. Liu M, Casimiro MC, Wang C, Shirley LA, Jiao X, Katiyar S, Ju X, Li Z, Yu Z, Zhou J, Johnson M, Fortina P, Hyslop T, Windle JJ, Pestell RG. P21cip1 attenuates ras-and c-myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci USA 2009; 106(45):19035-19039.
39. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins 2010; 2(11):2490-2518.
40. Christen V, Capelle M, Fent K. Silver nanoparticles induce endoplasmatic reticulum stress response in zebrafish. Toxicol Appl Pharmacol 2013; 272(2):519-528.
41. Christen V, Fent K. Silica nanoparticles and silver-doped silica nanoparticles induce endoplasmatic reticulum stress response and alter cytochrome p4501a activity. Chemosphere 2012; 87(4):423-434.
42. Miharada K, Sigurdsson V, Karlsson S. Dppa5 improves hematopoietic stem cell activity by reducing endoplasmic reticulum stress. Cell Rep 2014; 7(5):1381-1392.
43. van Galen P, Kreso A, Mbong N, Kent DG, Fitzmaurice T, Chambers JE, Xie S, Laurenti E, Hermans K, Eppert K, Marciniak SJ, Goodall JC, Green AR, Wouters BG, Wienholds E, Dick JE. The unfolded protein response governs integrity of the haematopoietic stem-cell pool during stress. Nature 2014; 510(7504):268-272.
44. Tonino SH, van Laar J, van Oers MH, Wang JY, Eldering E, Kater AP. Ros-mediated upregulation of noxa overcomes chemoresistance in chronic lymphocytic leukemia. Oncogene 2011; 30(6):701-713.
45. Landriscina M, Maddalena F, Laudiero G, Esposito F. Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxid Redox Signal 2009; 11(11):2701-2716.
46. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31(15):1869-1883.
47. Finkelstein AE, Walz DT, Batista V, Mizraji M, Roisman F, Misher A. Auranofin. New oral gold compound for treatment of rheumatoid arthritis. Annals of the rheumatic diseases 1976; 35(3):251-257.
48. Telford WG: Stem cell identification by dyecycle violet side population analysis. Methods Mol Biol 2013; 946:163-179.
49. Grabar KC, Freeman RG, Hommer MB, Natan MJ. Preparation and characterization of au colloid monolayers. Anal Chem 1995; 67(4):735-743.
50. Zhao Z, Tepperman K, Dorsey JG, Elder RC. Determination of cisplatin and some possible metabolites by ion-pairing chromatography with inductively coupled plasma mass spectrometric detection. J Chromatogr 1993; 615(1):83-89.